Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase
British Journal of Haematology, 07/05/2012
Muringampurath–John D et al. – Patients with Diffuse large B–cell lymphoma (DLBCL) in leukaemic phase present with high tumour burden and frequent involvement of extra nodal sites. In this uncommon DLBCL subgroup, anthracycline–based regimens with rituximab are associated with early morbidity and mortality, but yield approximately 50% 4–year survival.
